Monte Rosa Therapeutics (GLUE) Cash & Equivalents (2020 - 2026)

Monte Rosa Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $678.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 763.48% year-over-year to $678.1 million; the TTM figure through Mar 2026 stood at $678.1 million (up 763.48% YoY), while the FY2025 annual figure was $129.9 million, down 65.91% from the prior year.
• Cash & Equivalents was $678.1 million for Q1 2026 at Monte Rosa Therapeutics, up from $129.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $678.1 million in Q1 2026 to a low of $47.0 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $157.8 million across 5 years, with a median of $108.8 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents tumbled 82.88% in 2022, then jumped 763.48% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $54.9 million in 2022, then soared by 330.54% to $236.4 million in 2023, then soared by 61.14% to $381.0 million in 2024, then slumped by 65.91% to $129.9 million in 2025, then jumped by 422.08% to $678.1 million in 2026.
• The last three Cash & Equivalents figures came in at $678.1 million (Q1 2026), $129.9 million (Q4 2025), and $208.3 million (Q3 2025), per Business Quant data.